Answers are grounded in this paper and cite their sources.
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, amyloid-beta (Aβ) accumulation, and neuroinflammation.While classical hypotheses-the amyloid cascade, tau protein pathology, and chronic inflammation-have long been the predominant explanations of AD pathogenesis, recent evidence highlights the fundamental role of the gut microbiota in affecting brain health.This review article describes the pathway through which gut dysbiosis contributes to AD by elevated intestinal permeability, systemic inflammation, disruption of the blood-brain barrier (BBB), and altered production of microbial metabolites.Experimental findings indicate that microbial imbalance in animal models and human groups leads to reduced microbial diversity, elevated levels of proinflammatory cytokines, and increased amyloid pathology.Moreover, gut-derived metabolites such as short-chain fatty acids (SCFAs), bile acids, and neurotransmitters regulate microglial function, synaptic health, and Aβ formation.Therapeutic strategies aimed at the restoration of microbiota homeostasis-dietary intervention, probiotics, prebiotics, and fecal microbiota transplantation (FMT)have been successful in improving cognitive status and reducing neurodegeneration in preclinical models.Causality is still under investigation, but the microbiota-gut-brain axis is a productive area for future AD research and therapy.Further large-scale, long-term studies will be required to explain the mechanisms and to aid in the development of microbiota-based interventions.
No takes yet. Share an insight, caveat, or question.
Brzyska et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: